Skin Therapy Letter HOME
Written for dermatologists by dermatologists. Indexed by the US National Library of Medicine.
Skin Information
NETWORK
Skin Therapy Letter About STL Subscribe Today SkinCareGuide Network Site Map
CUSTOM DERMATOLOGY SEARCH:
Loading

Update on Drugs and Drug News - Number 2 1998


Class Name/Company Approval Dates and Comments

Anesthetic – topical

Lidocaine 2.5%, prilocaine 2.5%
Emla® patch
Astra

Emla® patches, previously approved by the FDA, are now launched in the US for the reduction of pain associated with injections in children aged over one month.

Psoriasis – severe recalcitrant plaque

Cyclosporin
SangCya®
Sangstat

Approved by the US FDA in October, 1998, SangCya® is the first generic formulation of cyclosporin to reach the market. Like Neoral®, it is approved for use in adult, non-immunocompromised patients who have failed to respond to at least one other systemic therapy.

Rosacea

Metronidazole lotion 0.75%
Metrolotion®
Galderma

Lotion dosage form was approved by the US FDA November, 1998 for the treatment of the inflammatory papules and pustules of rosacea.

Warts – External genital & perianal

Imiquimod
Aldara®
3M Pharmaceuticals

Aldara® is now available in the UK (its first European market), following approval by the UK Regulatory Agency in late 1998. It is already available in the US, Australia and New Zealand.

Wound closure

2-octylcyanoacrylate
Dermabond Topical Skin Adhesive®
Ethicon

Approved by the US FDA for closing lacerations and incisions that otherwise would require sutures, staples or skin strips.


Drug News

Aids-related Kaposi’s sarcoma

Alitretinoin gel 0.1%
Panretin®
Ligand

The FDA has issued Ligand Pharmaceuticals with a letter stating that Panretin® is approvable for the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma.

Antihistamines

Loratidine
Claritin®
Schering-Plough

Schering-Plough is taking action against Pfizer and UCB Pharma for the alleged breach of a 1996 settlement relating to marketing claims for cetirizine. Schering-Plough can claim that loratidine is non-sedating. Cetirizine’s labelling includes a warning about drowsiness, but Schering-Plough allege that Pfizer and UCB are promoting the drug as being non-sedating and less sedating than loratidine. (Scrip 2378, October 14, 1998)

Cetirizine
Zyrtec®
Pfizer

Herpes labialis

Penciclovir
Denavir®
SmithKline Beecham

A joint meeting of the US FDA’s Non-prescription Drugs and Antiviral Drugs Advisory Committees (NDAC and ADAC) voted against Denavir® being switched from prescription only to OTC.

Lyme disease

Lyme disease vaccine
LYMErix®
SmithKline Beecham

Awaiting approval by the FDA. Results from a pivotal study show that this vaccine is as effective in a six-month dosing schedule as in a 12-month schedule.


In this issue:

  1. Artecoll® – an injectable micro-implant for longlasting soft tissue augmentation
  2. Unanswered Questions in Antifungal Therapy for Onychomycosis
  3. Update on Drugs and Drug News - Number 2 1998